Tom 19, Nr 2 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-09-20
Wyświetlenia strony 949
Wyświetlenia/pobrania artykułu 22
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Inhibitory układu renina–angiotensyna–aldosteron — jak właściwie wybierać w 2022 roku?

Patryk Siedlecki1, Jarosław D. Kasprzak1
DOI: 10.5603/ChSiN.a2022.0005
Choroby Serca i Naczyń 2022;19(2):80-91.

Streszczenie

Inhibitory konwertazy angiotensyny (ACEI) oraz antagoniści receptora angiotensynowego (ARB) są grupami leków bardzo szeroko stosowanymi we współczesnej kardiologii i hipertensjologii. Mimo pozornych podobieństw leki te różnią się zasadniczo mechanizmem działania, co ma istotne znaczenie w praktyce klinicznej. W wielu wskazaniach preferowana opcja terapeutyczna to ACEI, w części sytuacji klinicznych obie grupy leków są w tej samej klasie zaleceń, natomiast nie ma obecnie wytycznych, w których postulowano by wyższość sartanów nad ACEI w leczeniu pierwszego rzutu. W nowej klasie leków, antagonistach receptora angiotensyny i inhibitorach neprilizyny, wykorzystuje się połączenie blokady receptora angiotensyny z blokadą neprilizyny. Wypadkowy efekt ich stosowania cechują duże podobieństwa do działania ACEI, dodatkowo wzbogacony o ochronę puli endogennych peptydów natriuretycznych.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006; 114(8): 838–854.
  2. Grajek S. Czy inhibitory receptora angiotensyny zwiększają ryzyko zawału serca? Krajobraz po badaniu ONTARGET. Kardiol Pol. 2008; 66: 1313–1324.
  3. Gong J, Sun Y, Xie L. ACEI/ARB drug therapy in COVID-19 patients: yes or no? J Transl Int Med. 2021; 9(1): 8–11.
  4. Kuba K, Imai Y, Ohto-Nakanishi T, et al. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010; 128(1): 119–128.
  5. Ma J, Shi X, Yu J, et al. Association of ACEi/ARB use and clinical outcomes of COVID-19 patients with hypertension. Front Cardiovasc Med. 2021; 8: 577398.
  6. Morales DR, Conover MM, You SC, et al. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. Lancet Digit Health. 2021; 3(2): e98–e114.
  7. Awad K, Zaki MM, Mohammed M, et al. Effect of the renin angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of 32 randomized controlled trials. Eur Heart J. 2021; 42(Suppl_1).
  8. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020; 106(19): 1503–1511.
  9. Semenzato L, Botton J, Drouin J, et al. Antihypertensive drugs and COVID-19 risk: a cohort study of 2 million hypertensive patients. Hypertension. 2021; 77(3): 833–842.
  10. Marko M, Pawliczak R. Noninferiority trials in clinical practice. Alergologia Polska — Polish Journal of Allergology. 2019; 6(4): 152–159.
  11. Yusuf S, Teo KK, Pogue J, et al. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358(15): 1547–1559.
  12. Savarese G, Costanzo P, Cleland JG, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiol. 2013; 61(2): 131–142.
  13. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67(5): 728–741.
  14. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71(19): e127–e248.
  15. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010; 123(11): 1016–1030.
  16. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl): 169S–173S.
  17. Brugts JJ, Arima H, Remme W, et al. The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease. Int J Cardiol. 2014; 176(3): 718–723.
  18. Borghi C, Veronesi M. Cough and ACE inhibitors: the truth beyond placebo. Clin Pharmacol Ther. 2019; 105(3): 550–552.
  19. Pinto B, Jadhav U, Singhai P, et al. ACEI-induced cough: a review of current evidence and its practical implications for optimal CV risk reduction. Indian Heart J. 2020; 72(5): 345–350.
  20. Franová S, Nosál'ová G, Antosová M, et al. Enalapril and diltiazem co-administration and respiratory side effects of enalapril. Physiol Res. 2005; 54(5): 515–520.
  21. Franova S. The influence of inhaled furosemide on adverse effects of ACE-inhibitors in airways. Bratisl Lek Listy. 2001; 102(7): 309–313.
  22. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  23. Tykarski A, Filipiak KJ, Januszewicz A, et al. Zasady postępowania w nadciśnieniu tętniczym — 2019 rok. Nadciś. Tętn. Prakt. 2019; 5(1): 1–86.
  24. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012; 33(16): 2088–2097.
  25. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300.
  26. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012; 59(6): 1124–1131.
  27. MacDonald TM, Williams B, Webb DJ, et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm‐based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc. 2017; 6(11).
  28. Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019; 37(9): 1768–1774.
  29. Rea F, Corrao G, Merlino L, et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018; 39(40): 3654–3661.
  30. Verma AA, Khuu W, Tadrous M, et al. Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Med. 2018; 15(6): e1002584.
  31. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019; 77(2): 71–159.
  32. Chow CK, Atkins ER, Hillis GS, et al. QUARTET Investigators. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021; 398(10305): 1043–1052.
  33. Gnanenthiran SR, Wang N, Di Tanna GL, et al. Association of low-dose triple combination therapy vs usual care with time at target blood pressure. JAMA Cardiology. 2022.
  34. Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127–1137.
  35. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370(9590): 829–840.
  36. Tóth K. PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014; 14(2): 137–145.
  37. Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011; 7: 777–787.
  38. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group, Authors/Task Force Members:, ESC Scientific Document Group, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  39. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  40. Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet. 2003; 362(9386): 772–776.
  41. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667–1675.
  42. Velazquez EJ, Morrow DA, DeVore AD, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380(6): 539–548.
  43. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21(8): 998–1007.
  44. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79(17): e263–e421.